(Spin Digit Editorial):- Vancouver, British Columbia Oct 19, 2021 (Issuewire.com) – Canam Biotech Inc. (the “Company”) is pleased to announce that on October 15, 2021, it has issued a total of 4,205,000 common shares to settle a total of $42,050 in outstanding consulting fees and debt owing by the company.
Settlements
The Company has settled $2,050 in past consulting fees owing through the issuance of 205,000 common shares to several consultants and 4,000,000 common shares to settle $40,000 in debt owing to a family trust controlled by J. Scott Munro, CEO, trustee. All shares have a fair value of $0.01 per share. All consultant shares were issued without resale restrictions pursuant NI 45-102 subsection 2.6(3) and the debt settlement shares are subject to the standard hold of four months plus one day in accordance with NI 45-102 section 2.3.
More on Spindigit:
- Light Up Your Day With Compelling Music Blogs and Exciting Music News
- Enjoy the Steamiest Music News Severed Hot Every Day
- KingZiLLa Is Showing His Skills with the Track ‘AH SUCKERPUSS DELICIOUS LOLLIPOP ADVENTURE’
- Maintain Healthy Lifestyle with Fitness Guru and Author Leo Costa Jr.
- IssueWire Offering Major Media Exposure in Business Press Release Distribution
For further information please contact
J. Scott Munro, CEO and director (Chairman)
E-mail: [email protected]
Cautionary Note Regarding Forward-Looking Information
This press release contains projections and forward-looking information that involve various risks and uncertainties regarding future events. Such forward-looking information can include without limitation statements based on current expectations involving a number of risks and uncertainties and are not guarantees of future performance of the Company. There are numerous risks and uncertainties that could cause actual results and the Company’s plans and objectives to differ materially from those expressed in the forward-looking information, including (i) the inability to complete the settlements; and (ii) other factors beyond the Company’s control. Actual results and future events could differ materially from those anticipated in such information. These and all subsequent written and oral forward-looking information are based on estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. Except as required by law, the Company assumes no obligation to update forward-looking information should circumstances or management’s estimates or opinions change.
Source :Canam Biotech Inc.
This article was originally published by IssueWire. Read the original article here.
